We also showed that patients with advanced LVDD have higher creatinine and potassium levels; these are important findings as chronic kidney disease and the potential subsequent hyperkalemia can limit the use of certain heart failure therapies, including SGLT2 inhibitors, MRAs, and RAAS inhibitors, which may be indicated in patients with LVDD. This evidence concerns the gene SLC5A2 and Hyperkalemia.